IC-CBAS

IC-CBAS (Ileocolonic-release Conjugated Bile Acid Sodium extract) is an oral, delayed-release formulation of conjugated bile acids derived from ox bile extract, containing approximately 35% taurocholic acid (TCA) and 21% glycocholic acid (GCA). Developed by the Mayo Clinic in collaboration with Satiogen Pharmaceuticals, the drug is designed to release its active components specifically in the ileum and colon. This targeted delivery activates the G protein-coupled bile acid receptor 1 (TGR5) and the farnesoid X receptor (FXR) on enteroendocrine L cells. The activation of these receptors stimulates the secretion of glucagon-like peptide-1 (GLP-1) and other satiety-inducing hormones, which helps regulate glucose homeostasis and reduce body weight. It has been investigated in Phase 1 clinical trials for the treatment of obesity and type 2 diabetes.

Other names

Ileocolonic-release conjugated bile acidIleocolic-released Conjugated Bile AcidConjugated bile acid sodium extractIleocolonic-release Conjugated Bile Acid Sodium extract